Consistently, xenograft study that investigated the effect of MYSM1 deficiency in 22Rv1 cells revealed a significant increase of tumor volume, suggesting an antitumorigenic role for MYSM1 in CRPC. This evidence concerns the gene MYSM1 and neoplasm.